Idiopathic nephrotic syndrome is the most frequent pediatric glomerular disease, affecting
from 1.15 to 16.9 per 100,000 children per year globally. It is characterized by massive …

Renal transplantation is now the best treatment for end-stage renal failure. To avoid
rejection and prolong graft function, organ recipients need immunosuppressive therapy. The …

The specific B-cell depleting anti-CD20 monoclonal antibody rituximab (RTX) is effective in
terms of the treatment of various immune-mediated glomerulopathies. The administration of …

Context Remission rates in young people with Graves hyperthyroidism are less than 25%
after 2 years of thionamide antithyroid drug (ATD). Objective We explored whether rituximab …

Immunoglobulin A vasculitis (IgAV) nephritis, also known as Henoch-Schönlein purpura
nephritis (HSPN), is a condition in which small blood vessel inflammation and perivascular …

Therapeutic monoclonal antibodies (MAbs) have been one of the fastest growing drug
classes in the past 2 decades and are indicated in the treatment of cancer, autoimmune …

The advantage of the newer biological therapies is that the immunosuppressive effect is
targeted, in contrast, to the standard, traditional immunomodulatory agents, which have a …

Objectives Rituximab is being increasingly prescribed for the treatment of autoimmune
glomerular diseases. While it is highly effective for some diseases, the response is less …

A complication of pediatric systemic lupus erythematosus (pSLE) is immune
thrombocytopenia (ITP). Although corticosteroids and immunoglobulins are frequently used …

Background: Minimal change disease and primary FSGS are podocytopathies but are also
immune-mediated diseases. Rituximab acts via multiple mechanisms by tilting the balance …